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Abstract. Murine and human leukocytes express sur- 
face glycoproteins, termed homing  receptors (HRs), 
containing lectin-like,  EGF-like (egf), and complement 
binding-like domains,  that apparently endow these 
cells with the ability to home to peripheral lymph 
nodes (pin's)  by virtue of an adhesive interaction with 
the pin postcapillary venule endothelium.  The murine 
pin HR was initially characterized with a rat monoclo- 
nal antibody, Mel  14,  that was specific for the murine 
form of the receptor.  This work demonstrated that Mel 
14 blocked the binding of murine lymphocytes to pin 
endothelium both in vitro and in vivo, a  result consis- 
tent with the possibility that this monoclonal antibody 
recognizes a region of the HR that is involved with 
endothelium recognition and adhesion.  In addition, 
this antibody also blocked the binding to the HR of 
PPME, a polyphosphomannan carbohydrate known to 
inhibit lymphocyte-pin endothelium interactions,  sug- 
gesting that Mel  14 may recognize the lectin domain 
of the pin HR. Here we show that,  while Mel 14 rec- 
ognized truncated HR containing both the lectin and 
egf domains,  antibody recognition was lost when the 
lectin domain alone was expressed.  Chimeric mole- 
cules, in which regions of the lectin domain of the 
non-Mel  14-reactive human pin HR were replaced 
with homologous regions of the murine pln HR, 
demonstrated that the Mel 14 recognition site is within 
the NH2-terminal 53 amino acids of the lectin domain. 
These results suggest that the Mel  14 monoclonal anti- 
body recognizes a determinant within the lectin do- 
main of the pln HR whose conformation may be de- 
pendent upon the presence of the egf domain.  Since 
Mel 14 efficiently blocks lymphocyte-endothelial inter- 
actions, these results support the hypothesis that the 
pln HR lectin domain may be directly involved with 
binding of lymphocytes to a carbohydrate ligand on the 
pin postcapillary venule endothelium. 
T 
HE trafficking of lymphocytes between the blood cir- 
culation  and  various  lymphoid organs  is  a  critical 
aspect of the immune system that allows for cells with 
various antigenic specificities  to be readily exposed to their 
cognate  antigenic  stimuli.  This  trafficking  is due,  in large 
part,  to  adhesive  interactions  between homing  receptors 
(HRs)  ~ on the lymphocyte cell surface and  ligands  on the 
high endothelium  of the postcapillary  venules of the various 
lymphoid organs (2, 8, 11, 29). Several lines of evidence sug- 
gest that peripheral  lymph nodes (pin's), gut-associated  lym- 
phoid tissues, synovial lymphoid tissues, and bronchial lym- 
phoid tissues depend upon different adhesive interactions  to 
accomplish tissue-specific  lymphocyte trafficking and hom- 
ing (4, 6, 7, 12, 13). It has been hypothesized that a diversity 
of lymphocyte HRs and endothelial  cell ligands might be the 
means by which this  lymphoid organ-specific  lymphocyte 
homing  is attained  (3,  14,  15). 
1. Abbreviations  used in this paper: cbd, complement binding-like  domain; 
egf domain, epidermal growth factor-like domain; HR, homing receptor; 
mHR-L, mHR-LE, and mHR-LEC,  the murine mHR lectin, leetin-egf,  and 
lectin-egf-cbd  domains,  respectively;  PCR,  polymerase  chain  reaction; 
PPME, polyphosphomannan ester. 
The most well-characterized  lymphocyte HR is the murine 
pin HR (mHR) (10). This 90-kD surface glycoprotein  was 
initially characterized  with a rat monoclonal  antibody, Mel 
14, and is here referred  to as gp90  ~' t4.  The Mel 14 anti- 
body was able to specifically block pin postcapillary  venule 
binding  of lymphocytes in both the in vitro frozen section 
(10) assay as well as in vivo in MRL-lpr/lpr mice (18), sug- 
gesting that it recognized  an adhesion  molecule involved in 
pin endothelium binding. In addition,  this antibody was able 
to block the binding of a polyphosphomannan ester, PPME, 
that was previously shown to inhibit lymphocyte-pin endo- 
thelium interactions  (31). This latter result suggested that the 
Mel 14 monoclonal  antibody might  recognize  a lectin-like 
molecule that  was involved with pin recognition,  a notion 
that was confirmed when a murine spleen eDNA encoding 
the antigen recognized  by Mel 14 was cloned (17, 24). This 
cDNA encoded a Mel 14-reactive surface glycoprotein,  as 
determined  by transient transfection analysis, that contained 
an NH2-terminal  lectin-like  domain  followed by an  EGF- 
like domain (herein referred to as egf domain), two repeats 
of a complement binding-like domain (cbd), a transmem- 
brane anchor,  and a short cytoplasmic domain.  The overall 
structure of the eDNA, together with previous data suggest- 
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was a sugar-inhibitable phenomenon (26, 27, 30), suggested 
that the cDNA corresponding to gp90  m~t t4 encoded a new 
class of molecules that may use lectin-sugar interactions to 
accomplish cell-cell adhesion. Subsequently, a human lym- 
phocyte cDNA showing a high degree of sequence homology 
with the murine pin HR cDNA was cloned (1) suggesting, in 
agreement with data regarding the sugar blocking of human 
lymphocyte-pin interactions as well as the lack of species 
specificity  for  lymphocyte-pin endothelium  interactions, 
that human immune cells home to pin using adhesive interac- 
tions similar to those used in the murine immune system (28). 
Because the Mel 14 antibody blocks lymphocyte-pin en- 
dothelium binding (10), determination of the gp90  m~ ~4 epi- 
tope recognized by this monoclonal antibody may have im- 
portant implications for characterizing the relative roles of 
the various pin HR protein domains in lymphocyte-endothe- 
lial interactions. Previous work indicated that this monoclo- 
hal antibody appeared to recognize a unique, branched form 
of ubiquitin in association with a gp90  m~ ~4 core sequence. 
These data included amino acid sequence analyses of im- 
munoaflinity-purified glO0  ~ ~4 which revealed a strong amino 
acid sequence signal that corresponded to the NH2 terminus 
of  the murine pin HR and a very weak signal corresponding to 
ubiquitin (23).  Perhaps more convincing was the isolation of 
a subset (~1%) of  ubiquitin-containing clones from a lambda 
gt 11 cDNA library that were reactive with the Mel 14 anti- 
body, a  result suggesting that a  relatively unique form of 
ubiquitin was recognized by Mel 14 (25).  In addition, anti- 
bodies directed against the bacterially produced material gen- 
erated from these Mel  14-positive lambda gt 11  ubiquitin 
clones reacted with cell surface components of various cell 
lines, although, surprisingly, the reactivity was not dependent 
upon the presence of gpg0  ~  ~4 (25).  In contrast to these 
results, subsequent analysis by our group did not reveal  a 
clear ubiquitin sequence when a gp90  m~m ~ antigen prepara- 
tion isolated from murine spleen by Mel 14 immunoaflinity 
chromatography was analyzed by gas phase-amino acid se- 
quencing (17). In addition, we also found that a human homo- 
logue of the murine pin HR was not reactive with Mel 14 
when transfected into mammalian cells (1), suggesting, if the 
antibody was indeed recognizing a unique form of ubiquitin, 
that this form could be  reproduced in a  bacterial  system 
(lambda gt 11), but could not be produced with a highly ho- 
mologous human glycoprotein in a mammalian cell expres- 
sion system. 
The work reported in this article describes the mapping of 
the Me114 recognition region on the murine pin HR. A com- 
bination of deletion mutants and murine-human chimeras 
demonstrates that this antibody recognizes an epitope con- 
tained within the first 53 amino acids of the lectin domain 
of gp90  mc~ t4  whose  recognition by  Mel  14  is  dependent 
upon the presence of the adjacent egf domain. These results 
are consistent with the notion that the lectin domain of the 
HR is critical for the recognition and binding of  lymphocytes 
to the postcapillary endothelium of pin. 
Materials and Methods 
Construction of  Recombinant Molecules 
Deletion mutants containing various domains of the murine pin HR were 
produced  by in vitro mutagenesis  of the pln HR eDNA (32).  Briefly, a 
double-stranded plasmid (pRK;  reference  9) containing an m13 origin of 
replication  was converted to a single-stranded  form by rescue with the m13 
helper phage K07. The resultant single-stranded  template was mutaganized 
by insertion of two adjacent stop condons (TAA and TAG) after amino acid 
positions 158 (the mHR lectin-like domain [mHR-L]),  193 (the mHR lectin- 
egf domain lmHR-LE]), and 332 (the mHR iectin-egf-cbd domain [mHR- 
LEC]) using in vitro mutagenesis  with 48-mer otigonucteotides  (32). The 
resultant constructs were transformed into bacteria, mutants were selected 
by hybridization with 32p 21-mer oligonucleotides,  and the DNA sequence 
of the mutants was determined by supercoil  sequencing,  mHR lectin-IgG 
and mHR lectin-egf-human IgG constant region chimeras were constructed 
by insertion of a human gamma 1 IgG constant region cassette (5) 3' to the 
mHR gene, and loop-out  in vitro mutagenesis of the resultant construct to 
give chimeras containing amino acids 1-158 of the routine pin HR (corre- 
sponding to the lectin domain) or amino acids 1-193 (corresponding to the 
lectin and egf domains) in translational phase with the hinge,  CH2, and 
CH3 regions  of the human lgG heavy chain. The Bgl II chimera (corre- 
sponding to amino acid 131) between the murine and human pin HR was 
produced by ligating an Eco RI-Bgl II fragment from the murine homing 
receptor to the homologous region of the human HR eDNA clone. An Mro 
I chimera (corresponding to amino acid 91) was produced  by ligating an 
NH2-terminal  Eco RI-Mro I fragment derived from the mHR eDNA by 
polymerase chain reaction (PCR) (22) using a 3' synthetic primer containing 
an Mro I site to the homologous  region of the human HR eDNA. Finally, 
an Mro l-Bgl lI chimera that replaced amino acids 91-131 of the human 
receptor with the homologous region of the murine receptor was constructed 
using a similar PCR mutagenesis  approach. 
Analysis of Constructs by Radioimmunoprecipitation 
Various constructs were  analyzed by immunoprecipitation of transfected 
293 cell superuatants  labeled with 3sS cysteine and methionine using Mel 
14 monoclonal antibody (1 #g/ml) or a polyclonal antibody directed against 
purified gp90  mc114 (the gift of Dr. Steven Rosen,  University of California, 
San Francisco) as previously described (17). Since the Mel 14 monoclonal 
antibody is a rat antibody, Mel 14 immunoprecipitations  were accomplished 
in the absence of protein A-Sepharose with rabbit anti-rat IgG polyclonal 
antibodies conjugated directly to Sepharose beads. Precipitation of  the mHR 
lectin-IgG and mHR lectin-egf-lgG chimeras was accomplished  with pro- 
tein A-Sepharose  beads in the absence of added antibodies. Immunoprecipi- 
tared glycoproteins  were analyzed on 7.5 or  10.0% polyacrylamide-SDS 
gels after reduction at 100°C with beta mercaptoethanol.  Immunoprecipita- 
tion of murine-human chimeric homing receptors was accomplished  using 
transfected  cell supernatants,  since previous work demonstrated  that the 
full-length murine and human HR cDNAs generated both membrane-bound 
and secreted forms of the receptor (17). Pulse-chase analysis was performed 
by labeling 293 cells that had been transfected with an expression plasmid 
encoding the cell-associated  form of the pin HR for 10 rain with 500 micro- 
curies each of 35S methionine and cysteine  in methionine--cysteine-free 
medium. The cells were washed and incubated for various times in methio- 
nine-cysteine-containing  medium, after which the cells were lysed with 1% 
NP-40 and immunoprecipitated  with either the Mel 14 monoclonal antibody 
(1 #g/ml) or with the rabbit polyclonal  antibody directed  against purified 
HR antigen. 
Results 
Pulse-Chase Analysis of the Me114 Epitope 
To examine the possibility of posttranslational modification 
of the pln HR and its role in Mel 14 antibody reactivity (23, 
25), pulse-chase experiments were performed. Cells were 
transfected with an expression plasmid encoding the full- 
length murine pin HR, pulse labeled with 3sS methionine 
and cysteine for 10 min, and chased in the presence of unla- 
beled amino acids for various periods of time. Cells were 
lysed, and the reactivity of labeled proteins with the poly- 
clonal anti-pin HR antibody and with Mel 14 was analyzed 
by immunoprecipitation. Fig. 1 shows that the pin HR is ini- 
tially produced as a lower molecular mass precursor of,',,80 
kD which is partially converted with time to a higher molec- 
ular mass glycoprotein of*90 kD. Glycosidase experiments 
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Mel  14 monoclonal antibody and anti-gp90  m~ ~4 polyclonal anti- 
bodies.  Cells were labeled for 10 min with 35S methionine and 
cysteine and chased for the indicated times in cold methionine- 
cysteine-containing media. The cells were lysed and the labeled 
glycoproteins were analyzed for reactivity with Mel 14 and poly- 
clonal anti-gp90  =*] J4 antibodies. Molecular mass markers in kD 
are  shown. M,  Mel  14 antibody reactivity;  P,  polyclonal anti- 
gp90~t ~4 reactivity. 
have shown that the lower molecular mass glycoprotein is a 
high mannose endoglycosidase H-sensitive precursor form, 
while the higher molecular mass antibody-reactive glycopro- 
tein is neuraminadase sensitive and localized on the cell sur- 
face (data not shown). This figure also clearly illustrates that 
the pin HR is reactive with both the polyclonal anti-pin HR 
antibody as well as with the Mel 14 monoclonal antibody at 
the initial time of  the chase, suggesting that if  the epitope rec- 
ognized by Mel 14 is a result of posttranslational modifica- 
tion of the pin HR core sequence then this modification must 
occur very rapidly after or cotranslationally with polypep- 
tide synthesis. 
Reactivity of  Me114 with pin HR Domain 
Deletion Mutants 
Previous work demonstrated the ability of the Mel 14 mono- 
clonal antibody to block both lymphocyte-pin high endo- 
thelium (10) interactions as well as the binding of PPME (31), 
a yeast cell wall polyphosphomannan carbohydrate known to 
inhibit this same cell-cell interaction. These data,  in con- 
junction  with  the  interesting domain-like structure of the 
gp90m~t t4 eDNA clone (17, 24), suggested that an investiga- 
tion of the interaction of this antibody with various gpg0  m~' ,4 
domain deletion mutants might provide some insights into 
the relative importance of these domains to pin endothelial 
cell recognition. Fig. 2  shows the various domain deletion 
mutants that were produced by in vitro mutagenesis. The de- 
letion of  the putative transmembrane domain in each of  these 
mutants was expected to allow for efficient secretion of the 
truncated proteins from transfected mammalian cells, an ex- 
pectation that was fulfilled (see below). The truncated pro- 
teins that were analyzed contained either the lectin-like, egf 
and cbd domains (mHR-LEC), or the lectin and egf domains 
(mHR-LE), or the lectin domain alone (mHR-L). 
Mammalian cells were transfected with each type of dele- 
tion mutant, and the secreted materials were analyzed with 
the Me114 monoclonal antibody as well as with a polyclonal 
antibody directed against the purified gp90  m*' t~ antigen. As 
can be seen in Fig. 3, the nontruncated, cell-associated mHR 
migrating at about 80--90 kD, and the secreted mHR-LEC 
(,080  kD)  and  mHR-LE  (multiple  glycosylated forms  at 
,030-40 kD) deletion mutants appeared to all be recognized 
by both the Mel 14 monoclonal antibody as well as the anti- 
gpg0~ ~4 polyclonal antibody.  However, neither antibody 
was  able  to  recognize the deletion mutant  containing the 
lectin-like domain alone (mHR-L). This result was consis- 
tent with one of three possibilities: the Mel 14 monoclonal 
antibody recognized an epitope at least in  part  cofftained 
within the egf domain; the Mel  14 antibody recognized a 
conformational determinant  in  the  lectin domain  that  re- 
quired the presence of the egf domain; the monoclonal anti- 
body recognized an epitope solely within the lectin-like do- 
main,  but  the  expressed  protein  was  unstable  and  was, 
therefore, not detectable by the antibody. 
The third of these possibilities was examined by producing 
lectin- and lectin-egf-containing deletion mutants that could 
be detected by other means. Chimeric molecules containing 
the lectin-like and lectin-egf domains of the gp90  men4 cDNA 
clone and the hinge, CH2, and CH3 regions of the human 
gamma 1 IgG were constructed (Fig. 2, mHR-L+ lgG, mHR- 
LE+IgG) (5). Because of the efficient reactivity of the IgG 
constant region with Staphylococcal protein A antigen, these 
chimeric molecules could be easily detected by precipitation 
of transfected cell supernatants  with protein A-Sepharose 
beads in the absence of added antibodies (5). As can be seen 
Figure 2. Construction of various truncated mHR and mHR+IgG 
chimeras. The original mHR eDNA was mutagenized by in vitro 
mutagenesis with  oligonucleotides containing two adjacent stop 
codons (TAA and TAG) after amino acid positions 158 (the mHR- 
lectin-like domain  [mHR-L]),  193  (the mHR lectin-egf domain 
[mHR-LE]),  and  332  (the  mHR-lectin-egf-cbd domain  [mHR- 
LEC]). mHR +  IgG chimeras were produced by in vitro loop-out 
mutagenesis of plasmids containing the original mHR eDNA and 
a human gamma  1 IgG-containing cassette (5) located 3' of the 
mHR eDNA. Oligonucleotides were designed to loop out the region 
between the mHR lectin domain and IgG hinge, CH2, and CH3 
regions (mHR-L + IgG), or the mHR egf domain and IgG hinge, 
CH2, and CH3 regions (mHR-LE + IgG). TMD, transmembrane 
anchor domain. 
Bowen et al. Mel 14 Antibody Recognition Site  149 Figure 3. Reactivity of various HR domain deletion mutants with 
the Mel  14 monocional and anti-gp90 me~ ~4 polyclonal antibodies. 
Plasmids containing the various deletion mutants were transfected 
onto the 293 kidney cell line and the cells were labeled with 35S 
methionine and cysteine. Since deletion of the transmembrane an- 
chor sequence from the mHR constructs should result in efficient 
secretion of the glycoproteins, cell supernatants were immunopre- 
cipitated with Me114 monoclonal antibody, or with a polyclonal an- 
tibody directed against purified gp90 ~t ~4 as described previously. 
The resultant immunoprecipitates were analyzed on 10 % polyacryl- 
amide-SDS Gels. Molecular mass markers in kD are shown. (Lane A) 
Cell lysates expressing native (i.e., nontruncated) mHR, gp90  me~ t4 
polyclonal antibody; (lane B) cell lysates expressing native mHR, 
Mel  14 antibody;  (lane C) mHR-LEC, gp90  me~ ~4 polyclonal anti- 
body; (lane D) mHR-LEC, Mel  14 antibody;  (lane E) mHR-LE, 
gp90mo~ ~4 polyclonal antibody;  (lane F) mHR-LE, Mel  14 anti- 
body; (lane G) mHR-L, gp90  ~e~ 14 polyclonal antibody;  (lane H) 
mHR-L, Mel  14 antibody. 
tage of this fact to further map the Mel 14 recognition region 
by producing chimeric molecules where portions of the mu- 
rine lectin domain replaced homologous regions from the 
human lectin domain. As can be seen in Fig. 5, the first such 
chimera took advantage of a Bgl 1I restriction site at amino 
acid  131  (amino acid 93 of the mature molecule) that was 
shared  by  both  the  human  and  murine  forms of the  HR 
(mhHR Bgl 1I). A second chimera (mhHR Mro I) was pro- 
duced by insertion of an Mro I  site in the marine receptor 
cDNA at amino acid 91 (amino acid 53 of the mature mole- 
cule) by PCR mutagenesis (22) such that this site could be 
joined to a homologous site in the human form of the recep- 
tor. Finally, a third chimera produced by PCR mutagenesis 
replaced the region corresponding to amino acids 91-131  of 
the human receptor with the homologous region from the 
murine receptor mhHR (Bgl II-Mro I). 
Fig. 5 shows radioimmunoprecipitation analysis of  the var- 
ious murine-human chimeric HRs. Transfected cell superna- 
tants were analyzed for reactivity with either the murine- 
specific Mel 14 antibody or the murine- and human-reactive 
polyclonal  anti-gp90  ~  14  antibody,  since  we  previously 
demonstrated that both transfected cells as well as cells nor- 
mally synthesizing both the murine and human HR produce 
secreted forms, albeit relatively inefficiently, of the proteins 
that apparently correspond to extracellular domains cleaved 
at or near the transmembrane anchor region (17). As can be 
seen in this figure, the ,oS0-kD murine receptor reacts with 
both the Mel 14 monoelonal antibody as well as the gp90  ~  ~4 
polyclonal antibody, while the ,o70-kD human receptor reacts 
only with the gp90  ~  t4 polyclonal antibody,  in  agreement 
with previous fluorescence-activated cell sorter analysis (1). 
The difference in molecular mass between the two shed re- 
ceptors was most likely due to the fewer potential  NH2-1inked 
glycosylation sites found in the human vs. the murine recep- 
tors (1,  16). In addition, the relatively weak reactivity of the 
in Fig. 5, chimeric proteins of •50  kD (mHR-L+IgG)  and 
,o60 kD (mHR-LE+IgG)  molecular mass were efficiently 
produced in transfected mammalian cell lines as protein A- 
reactive,  secreted molecules (the fainter,  higher molecular 
mass bands are reduction-resistant multimers (Fermie, C., 
and L. Lasky, unpublished observations). The fact that these 
molecules  were  efficiently  secreted  demonstrates  that  the 
gp90~t i, signal sequence was functioning normally in the 
context  of these  constructs.  However,  Fig.  4  shows  that, 
while the mHR-LE+IgG construct could be recognized by 
the Mel 14 antibody, the mHR-L+IgG was unable to interact 
with Mel 14, in agreement with results shown in Fig. 3, sug- 
gesting that the apparent lack of reactivity by the lectin con- 
struct was not due to instability of this deletion mutant. 
Reactivity of  Mel 14 with Murine-Human 
pin HR Chimeras 
Previously, we described a human homologue of the murine 
pin HR that was isolated from a peripheral blood lymphocyte 
library (1). This homologue contained an identical domain 
structure to that discovered for the murine pin HR. In addi- 
tion,  while the overall sequence homologies, especially in 
the lectin-like and egf domains,  were quite high (,'o85%), 
cells transfected with the human homologue showed no reac- 
tivity with the Mel 14 antibody (at 1 #g/ml). We took advan- 
Figure 4.  Reactivity of mHR 
+  IgG chimeras with protein 
A-Sepharose and with the Mel 
14 monoclonal antibody. 293 
cells  were  transfected  with 
plasmids  encoding  mHR  + 
IgG chimeras and labeled with 
35S  methionine  and  cysteine. 
Cell  supernatants  were  ana- 
lyzed  with protein  A-Sepha- 
rose in the absence of added 
antibody or with Mel 14 mono- 
clonal  antibody  and  rabbit 
anti-rat  IgG polyclonal  anti- 
body  conjugated  directly  to 
Sepharose  beads.  Molecular 
mass markers in kD are shown. 
(Lane A) mHR-LE + IgG, pro- 
tein  A;  (lane  B)  mHR-L  + 
IgG, Mel 14; (lane C) mHR- 
LE  +  IgG, protein  A;  (lane 
D) mHR-LE +  IgG, Mei  14. 
The Journal of Cell Biology, Volume 110, 1990  150 Figure 5. Construction of murine-human  HR chimeric molecules. 
Previous work demonstrated that a human cDNA (hHR) encodes 
a lymphocyte glycoprotein that is highly similar to the murine pin 
HR (mHR), but that does not react with the Mel 14 monoclonal an- 
tibody (1). mHR Bgl II was constructed by replacing the hHR region 
corresponding to amino acids  1-131 with the homologous region 
from the murine receptor, mHR Mro I was constructed by replacing 
the hHR region corresponding to amino acids 1-91 with the corre- 
sponding region of the mHR produced by PCR mutagenesis Mro 
I-Bgl II was produced by replacing the region corresponding to 
amino acids 91-131 of the hHR with the corresponding region of 
the murine receptor using PCR mutagenesis. 
human HR was probably due to poor cross-reactivity between 
the anti-murine gp90  m~ 14 polyclonal antibody and the hu- 
man HR homologue (1). Fig. 6, lanes I and J, shows that the 
construct containing the first 131 amino acids (including the 
signal sequence) of  the murine receptor (mhHR Bgl II) reacts 
with both monoclonal and polyclonal antibodies, suggesting 
that the Mel 14 epitope is contained within the first 93 amino 
acids of the mature (i.e., signal sequence-cleaved) receptor. 
A chimeric protein containing the first 53 amino acids of the 
mature receptor (mhHR Mro I; Fig. 6, lanes G and H) also 
reacts with both antibodies, while a chimera that contains the 
first 53 amino acids of the human receptor followed by 42 
amino acids of the murine receptor (rnhHR Bgl H-Mro I; 
Fig. 6, lanes E and F) shows reactivity only with the poly- 
clonal antibody. These results in combination unambiguously 
assign at least part of the Mel 14 epitope to the first 53 amino 
acids of the murine homing receptor. 
Discussion 
The data reported in this article demonstrate that the Mel 14 
monoelonal antibody recognizes an  epitope contained,  at 
least in part, within the lectin domain of the murine pin HR. 
This result is entirely consistent with previous data which 
demonstrated that this monoclonal antibody blocks the bind- 
ing of PPME (30), a polyphosphomannan carbohydrate, pre- 
sumably to the carbohydrate-binding lectin domain of the 
lymphocyte surface-locaiized gp90  ~  14 HR. When taken in 
the context of the ability of this same antibody to block the 
binding of lymphocytes to pin high endothelium both in vitro 
(10) and in vivo (18), the results reported here imply that the 
lectin domain is directly involved in the adhesive interaction 
between lymphocytes and the pin endothelium. This latter 
notion is consistent with previous work demonstrating that 
sialidase treatment of lymph node sections in vitro (20) or 
of lymph nodes in vivo (21) abolishes the adhesive interaction 
between lymphocytes and pin endothelium, possibly by de- 
stroying a uniquely located sialic acid-containing oligosac- 
charide recognized by the pin HR lectin domain. 
The finding that removal of the egf domain abolishes the 
ability of Mel 14 to recognize the lectin region of the HR sug- 
Figure 6.  Radioimmunoprecipitation analysis 
of murine-human  chimeric  HRs. The con- 
structs shown in Fig. 4 were transfected onto 
293 cells, and the cells were labeled with 3~S 
cysteine and methionine. Since previous work 
had demonstrated that both transfected cells as 
well as cell lines normally synthesizing both 
the murine and human HR produce secreted 
forms of the molecules, labeled cell superna- 
tants were analyzed for reactivity with both the 
Mel 14 monoclonal antibody (1 #g/ml), specific 
for the murine form of the receptor, as well as 
with  a  polyclonal  antibody  directed  against 
purified  gp90  ~l ~4,  which  reacted with  both 
murine and human receptors. (Lane A) Secreted 
gp90m~l t4, Mel 14 antibody; (lane B) secreted 
go90m~ 14, gp90m~l  ~4 polyclonal antibody; (lane 
C) human HR, Mel 14 antibody; (lane D) hu- 
man HR, gp90  m~l t4 polyclonal antibody; (lane 
E) mhHR Mro l-Bgl II, Mel 14 antibody (lane 
F) mhHR  Mro l-Bgl  II,  gp90  m~i  14  polyclonal 
antibody,  (lane  G) mhHR  Mro 1,  Mel 14  anti- 
body, (lane  H) mhHR  Mro I,  gp90  '~114  poly- 
clonal  antibody;  (lane  I)  mhHR Bgl H, Mel 14 
antibody; (lane  3) mhHR  Bgl H, gp90  ~t 14 
polyclonal  antibody; (lane K) mock transfected, 
Mel  14 antibody; (lane L) mock transfected, 
gp90~e~ 14 polyclonal antibody. 
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tibody is potentially quite interesting. If it is assumed that a 
unique ubiquitin-HR linkage within the lectin domain is the 
Mel  14 epitope (23),  then it would appear that either the 
structure of the ubiquitinated epitope or the actual ubiquiti- 
nation of the site may be dependent upon sequences within 
the egf domain. Since it was previously shown that Mel 14 
can apparently recognize bacterially produced ubiquitin in the 
absence of any egf sequences, the former of these two possi- 
bilities is clearly not tenable (25).  Thus, if the notion that 
ubiquitin comprises part of the Mel 14 epitope is accepted, 
then it seems clear that the egf domain must have some effect 
on the ubiquitination of the site within the lectin domain. 
An alternative possibility is that the epitope recognized by 
Mel 14 is not actually a unique form of ubiquitin. One argu- 
ment for this possibility is the lack of Mel 14 reactivity with 
the human homologue of the pin HR. The high degree of se- 
quence homology between these two lectin domains (•  85 %) 
(1), together with the fact that our transient transfection sys- 
tem can clearly produce a Mel 14-reactive murine HR (17), 
is difficult to reconcile with a unique ubiquitinated epitope, 
since it might be assumed that the invariant nature of the 
ubiquitin primary sequence would be such that this uniquely 
linked form of ubiquitin should also be found on the human 
homologue. An additional argument against a ubiquitin-like 
epitope is the pulse-chase experiment described in Fig.  1 
which  suggests  that  ubiquitin  would  have  to  be  added 
cotranslationally to the core sequence, a possible, although 
as yet undescribed, mechanism of ubiquitination (19). In ad- 
dition,  we  have failed to  demonstrate antiubiquitin poly- 
clonal antibody reactivity with cells that are highly positive 
for reactivity with both Mel 14 monoclonal and polyclonal 
anti- gp90  ~t  t4 antibodies (Lasky, L., and S.  Stachel, un- 
published observations). Finally, although we have been un- 
able to reproduce the Mel  14 epitope by expression of the 
murine pin HR cDNA sequence in an Escherichia  coli ex- 
pression  system (Fennie,  C.,  and  L.  Lasky, unpublished 
observations), it can be argued that the protein is not glyco- 
sylated and/or correctly folded in bacterial expression sys- 
tems. Alternatively, the relatively minor amino acid differ- 
ences between the human and murine receptors might be 
sufficient to disrupt the binding of the ubiquitinated site in 
the human HR to the Mel 14 antibody, although the recogni- 
tion of divergent lambda gt 11 ubiquitin clones by Mel  14 
(25) seems to argue against this. We thus feel the nature of 
the Mel 14 recognition sequence remains somewhat contro- 
versial. 
If  one assumes that ubiquitin is not actually part of the Mel 
14 recognition site, then the lack of Mel 14 recognition of 
the truncated HR missing the egf domain may be interpreted 
in one of two ways. One possibility is that the egf domain in- 
duces the lectin domain to assume a conformation that is rec- 
ognized by Mel 14. Alternatively, the Mel 14 recognition site 
may contain distantly located sequences derived from both 
the lectin-like and egf domains. The argument against the 
latter possibility is the binding of Mel 14 to the murine-hu- 
man chimera, where the egf  domain derived from the human 
HR contains a  number of amino acid substitutions when 
compared to the murine HR egf domain (6 changes out of 
34 total residues). Thus, if the egf domain is actually a com- 
ponent of the Mel 14 epitope, then this antibody must recog- 
nize one of the relatively small egf regions found to be con- 
served  between  the  human  and  murine  receptors.  An 
additional argument in favor of the role of the egf domain in 
inducing an appropriate conformation on the lectin domain 
is the finding that deletion of a similar egf domain from tis- 
sue plaminogen activator results in mutant molecules with 
decreased substrate-binding activities (16). We thus favor the 
possibility that Mel  14 recognizes a conformational deter- 
minant in the murine pin HR and that one of the functions 
of the egf domain is to induce an appropriate conformation 
in the lectin domain. 
In conclusion, the data reported here suggest that the Mel 
14 monoclonal antibody recognizes a determinant within the 
NH2  terminal  region  of  the  murine  HR  lectin  domain 
whose conformation may be dependent upon the presence of 
the egf domain. The binding of this cell adhesion-blocking 
monoclonai antibody to the lectin domain of  the pin HR sug- 
gests a direct involvement of this domain in endothelial cell 
recognition by lymphocytes, a possibility that we are cur- 
rently testing by direct binding of various soluble HR to pln 
endothelium. 
Received for publication 3 August 1989 and in revised form 28 September 1989. 
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